Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 11, 2024 (filed on Apr 12, 2024)Insider Name:Lurker NancyOwnership Type:Direct OwnershipSecurities:Non Qualified Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:22,103Price:--
-
Apr 11, 2024 (filed on Apr 12, 2024)Insider Name:Lurker NancyOwnership Type:Direct OwnershipSecurities:Restricted Stock Unit AwardNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:11,255Price:--
-
Apr 11, 2024 (filed on Apr 12, 2024)Insider Name:Lurker NancyOwnership Type:Direct OwnershipSecurities:Non Qualified Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,833Price:--
-
Apr 11, 2024 (filed on Apr 12, 2024)Insider Name:Lurker NancyOwnership Type:Direct OwnershipSecurities:Restricted Stock Unit AwardNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,323Price:--
-
Mar 18, 2024 (filed on Mar 18, 2024)Insider Name:Nichols Christian ToddOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,417Price:$28.10
-
Feb 27, 2024 (filed on Feb 27, 2024)Insider Name:Parisi Samuel JosephOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,559Price:$29.65
-
Feb 26, 2024 (filed on Feb 27, 2024)Insider Name:Nichols Christian ToddOwnership Type:Direct OwnershipSecurities:Restricted Stock Unit AwardNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:21,638Price:--
-
Feb 26, 2024 (filed on Feb 27, 2024)Insider Name:Nichols Christian ToddOwnership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:87,602Price:--
-
Feb 26, 2024 (filed on Feb 27, 2024)Insider Name:Parisi Samuel JosephOwnership Type:Direct OwnershipSecurities:Restricted Stock Unit AwardNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10,986Price:--
-
Feb 26, 2024 (filed on Feb 27, 2024)Insider Name:Parisi Samuel JosephOwnership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,890Price:--
Filings by filing date
-
Apr 11, 2024 (filed on Apr 12, 2024)Insider Name:Lurker NancyOwnership Type:Direct OwnershipSecurities:Non Qualified Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:22,103Price:--
-
Apr 11, 2024 (filed on Apr 12, 2024)Insider Name:Lurker NancyOwnership Type:Direct OwnershipSecurities:Restricted Stock Unit AwardNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:11,255Price:--
-
Apr 11, 2024 (filed on Apr 12, 2024)Insider Name:Lurker NancyOwnership Type:Direct OwnershipSecurities:Non Qualified Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,833Price:--
-
Apr 11, 2024 (filed on Apr 12, 2024)Insider Name:Lurker NancyOwnership Type:Direct OwnershipSecurities:Restricted Stock Unit AwardNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,323Price:--
-
Mar 18, 2024 (filed on Mar 18, 2024)Insider Name:Nichols Christian ToddOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,417Price:$28.10
-
Feb 26, 2024 (filed on Feb 27, 2024)Insider Name:Nichols Christian ToddOwnership Type:Direct OwnershipSecurities:Restricted Stock Unit AwardNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:21,638Price:--
-
Feb 26, 2024 (filed on Feb 27, 2024)Insider Name:Nichols Christian ToddOwnership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:87,602Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Nichols Christian ToddOwnership Type:Direct OwnershipSecurities:Restricted Stock Unit AwardNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-6,407Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Nichols Christian ToddOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,845Price:$29.57
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Nichols Christian ToddOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:6,407Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Connaught HSE, 1 Burlington Road DUBLIN 00000 |
Tel: | N/A |
Website: | https://www.alkermes.com |
IR: | See website |
Key People | ||
Richard F. Pops Chairman of the Board, Chief Executive Officer | Iain M. Brown Chief Financial Officer, Senior Vice President | Blair C. Jackson Chief Operating Officer, Executive Vice President |
David Joseph Gaffin Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary | Craig C. Hopkinson Executive Vice President, Research and Development and Chief Medical Officer | Michael J. Landine Senior Vice President - Corporate Development, Chief Risk Officer | C.Todd Nichols Senior Vice President, Chief Commercial Officer |
Business Overview |
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio. |
Financial Overview |
For the fiscal year ended 31 December 2023, Alkermes Plc revenues increased 50% to $1.66B. Net income before extraordinary items totaled $519.2M vs. loss of $33.2M. Revenues reflect Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA segment increase from $115.7M to $486.1M, LYBALVI segment increase of 100% to $191.9M, United States segment increase of 60% to $1.49B. Net Income reflects Interest Income increase from $7.6M to $30.9M (income). |
Employees: | 2,100 as of Feb 9, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $3,489M as of Dec 31, 2023 |
Annual revenue (TTM): | $1,663M as of Dec 31, 2023 |
EBITDA (TTM): | $495.05M as of Dec 31, 2023 |
Net annual income (TTM): | $519.16M as of Dec 31, 2023 |
Free cash flow (TTM): | $353.31M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 169,184,183 as of Mar 18, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |